Product Details
Amino Acid Sequence:D-Arg-2′,6′-dimethyl-Tyr-Lys-Phe-NH2
Molecular Formula:$C_{32}H_{49}N_{9}O_{5}$
Molecular Weight:639.8 g/mol
PubChem CID:11764719
CAS Number:736992-21-5
Contents:Lyophilized powder, white/off-white color
Price range: $106.00 through $348.00 / 10 Vials
SS-31 peptide, also known asElamipretide or Bendavia , is a synthetic research peptide that has been widely studied for its role in mitochondrial function and cellular energy regulation research models.
Due to its unique ability to associate with mitochondrial membranes in experimental settings, SS-31 has become a key reference peptide in cellular metabolism, oxidative stress, and bioenergetics research.
In laboratory environments, SS-31 is frequently used to explore mitochondrial efficiency, cellular energy balance, and stress-response pathways, making it a valuable tool in advanced biochemical and cellular research.
Amino Acid Sequence:D-Arg-2′,6′-dimethyl-Tyr-Lys-Phe-NH2
Molecular Formula:$C_{32}H_{49}N_{9}O_{5}$
Molecular Weight:639.8 g/mol
PubChem CID:11764719
CAS Number:736992-21-5
Contents:Lyophilized powder, white/off-white color
| Size | 50mg, 10mg |
|---|---|
| Mechanism of action | In experimental research, SS-31 is often described as a peptide that interacts with mitochondrial inner membrane components, making it useful for studying: ✔ Mitochondrial structural stability These characteristics have made SS-31 a frequently referenced peptide in mitochondria-centered research fields. |
| Storage & handling | Storage:Store the lyophilized vial in a cool, dry area protected from direct sunlight. |
Only logged in customers who have purchased this product may leave a review.
All products on this site are for laboratory research, development, or analytical use only; they are NOT FOR HUMAN CONSUMPTION, medical, diagnostic, cosmetic, or veterinary applications.
These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease. Genixpep is not a compounding or outsourcing facility under sections 503A/503B of the FD&C Act.
Reviews
There are no reviews yet.